TILT Biotherapeutics Ltd

We are proud to announce that TILT was selected by the European Innovation Council (EIC) as one of the best companies for funding. The equity investment will be made through the EIC Fund. With the significant 2-CREATE project funding we are moving to Phase II clinical studies & towards cancer care with TILT-123. Thank you EIC Accelerator and our evaluators! This EU-level funding is vital to keep TILT Biotherapeutics competitive globally #EUeic #Biotech #Pharma #Oncology EIC Accelerator – 68 deep-tech start-ups in the latest funding round - European Commission (europa.eu)

🔬 Exciting News from Clinical Cancer Research! 🔬 We're thrilled to share an editorial comment has been published in Clinical Cancer Research (https://lnkd.in/dFTqVvuq) regarding our recent publication (https://lnkd.in/dhWKEwe3) on TILT-123 used as monotherapy in a Phase I trial! Independent experts in the field have highlighted the promising results of our study, which tested an oncolytic adenovirus armed with tumor necrosis factor-α and interleukin-2 in patients with advanced solid tumors. The authors concluded that "TILT-123 seems to be a promising candidate to join the still short list of approved oncolytic viruses," underscoring the significance of our findings in advancing cancer treatment. This recognition highlights our commitment to advancing innovative therapies in oncology and bringing hope to patients facing challenging conditions. This type of research is conditional to the patients who volunteer to advance cancer treatment, a big thank you them! Also to our dedicated team and collaborators for their hard work and expertise! #ClinicalTrial #OncolyticVirotherapy #CancerResearch #InnovationInMedicine #ClinicalCancerResearch

👇We’re excited to share an article in @ONCOLife on "How Engineered Viruses Could Transform Cancer Treatment." https://lnkd.in/gu9tW4XW 🔍TILT-123 is genetically modified to specifically target and destroy #cancer cells. 💉IV administration of TILT-123 increases patient access, simplifies logistics, and targets cancer metastases more effectively. 👩⚕️Ongoing Phase 1B trials in ovarian and lung cancer in combination with pembrolizumab have the potential to redefine cancer treatment. @American Society of Clinical Oncology (ASCO), @Hüseyin Kandemir #Biotech #Pharma #Innovation #Oncology #ClinicalTrials https://lnkd.in/dTyHEfu9

Haemme reipasta tiimiläistä määräaikaiseen työhön osakkeiden hallinnan pariin elo-marraskuulle https://lnkd.in/dFGUHHSE

We are excited to announce that we have successfully secured the first tranche for our Series B financing! The €12M financing was completed in a record time in collaboration with Springvest Oyj. Thank you to all of the many private investors who participated and to our cornerstone investors Lifeline Ventures, Tesi, and Stephen Industries also involved in the Series B. 🔬 Discover our patented TILT® technology: https://tiltbio.com/ #Biotech #Pharma #Innovation #Oncology #ClinicalTrials #OvarianCancer

Check out our two posters highlighting promising clinical data on TILT-123 at #ASCO2024, presented by Dafne Quixabeira and João M.! Poster #433 demonstrates how TILT-123, in combination with KEYTRUDA®, was safe and achieved a disease control rate of 64.3% in patients with platinum-resistant or refractory ovarian cancer, with some patients experiencing long-term survival. 📝https://lnkd.in/e9-FtBvj Poster #137 highlights TILT-123's potential as a systemic therapy, showcasing its ability to target tumours effectively when administered intravenously. 📝https://lnkd.in/eyqz8FzE Our vision is to revolutionize cancer treatment by altering the tumor microenvironment to stimulate the body's immune response against cancer. #Biotech #Innovation #Pharma American Society of Clinical Oncology (ASCO)

Exciting news from upcoming #ASCO24! We’re presenting promising data on TILT-123 in ovarian cancer, reinforcing it’s potential to be developed as a systemic therapy. Our Phase 1 trial results demonstrate that TILT-123, in combination with KEYTRUDA®, is safe . It has achieved disease control in 64.3% of patients with platinum-resistant or refractory ovarian cancer and demonstrated long term survival in some patients.  Additionally, TILT-123's Phase 1 clinical results as an intravenous therapy proves its capability to target tumors systemically.  Join us at ASCO to discover how we’re providing new hope for cancer patients with limited treatment options. 🔗 Read our Press Release: https://lnkd.in/eCsj6xku 📝Abstract (5562) – Poster #433 presented 3 June at 09:00-12:00: https://lnkd.in/ejBbmTKv 📝Abstract (2658) – Poster #137 presented 1 June at 09:00-12:00: https://lnkd.in/ei6wSyMB #Pharma #Biotech #Oncology #Innovation American Society of Clinical Oncology (ASCO) 

Join us at #ASCO24 from May 31 – June 4 in Chicago: bd@tiltbio.com Dafne Quixabeira and João M. are presenting two posters on the use of TILT-123, our patented #oncolytic #immunotherapy technology. Also, connect with our VP of Business Development Victor Cervera and US Clinical Lead John Goldfinch to learn how TILT unlocks the immune system’s full potential to fight cancer by modifying the tumour microenvironment. 📅June 1 | 09:00 – 12:00 | #137: Intravenous delivery of oncolytic adenovirus TILT-123 results in systemic tumor transduction and accumulation of lymphocytes. 📅June 3 | 09:00 – 12:00 | #433: PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer. 🤝 Schedule a 1-1 with Victor: bd@tiltbio.com 🔗  Register for ASCO 2024: https://lnkd.in/gAiEMCv #Pharma #Biotech #Innovation #Oncology American Society of Clinical Oncology (ASCO)